

REMARKS


This amendment and remarks are in response to the Office Action of April 6, 2007. Claims 41-65 have been given a second restriction requirement. It was unclear to Applicants if the second restriction requirement was in place of, or in addition to the original restriction requirement. In a phone conversation with Examiner Barnhardt on June 14, 2007, it was confirmed that the second restriction requirement was in place of the original restriction despite the language in the second paragraph stating it was a "further restriction." In light of that information, the Applicants elect Group 1 and Example 51, and provide new claims to comply with the group "drawn to compounds where Q3-Q6 are C atoms and Rc (as R4) = monocyclic rings." In this new replacement restriction requirement there is no limitation provided for Q<sup>1</sup> and Q<sup>2</sup>. Accordingly, new claims 66-85, which are a restricted version of the originally-filed provisional application, are provided.

Applicants' attorney sincerely and respectfully requests that the Examiner consider, a telephone (805-447-3299) or personal interview to resolve any outstanding issues deemed appropriate by the Examiner.

Please send all future correspondence to:

US Patent Operations/RVP  
Dept. 4300, M/S 28-2-C  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

Respectfully submitted,



Richard V. Person  
Attorney for Applicants  
Registration No.: 42,991  
Phone: (805) 447-3299  
Date: June 15, 2007